CORRECTION

Pancreatic cancer: molecular pathogenesis and new therapeutic targets

Han H. Wong & Nicholas R. Lemoine

Original article Wong, H. H. & Lemoine, N. R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. *Nat. Rev. Gastroenterol. Hepatol.* 6, 412–422 (2009).

In the July 2009 issue of *Nature Reviews Gastroenterology & Hepatology*, several errors were published in the Review article by Han H. Wong and Nicholas R. Lemoine. In Table 1, the targets Ras, Notch3 and SMAD4 should be displayed as *KRAS*, Notch 3, and *SMAD4*. On page 2, the 49th line of the right-hand column should read "...antisense inhibitors, such as ISIS 3521 and oblimersen...". In Figure 2, RAF should be displayed as Raf. On page 5, line 6 of the right-hand column, AKT2 should be displayed as *AKT2*. On page 7, the 4th line of the left-hand column should read '...KRas increases the therapeutic effect of IGF-I receptor antisense oligonucleotide.' In addition, the 10th line in the second paragraph of the right-hand column should read '...Ras, EGFR and TGF- α signaling...', and the 18th line should read "... γ -secretase inhibitor (L-685,458)...".

doi:10.1038/nrgastro.2009.123